Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.

Although the overall number of acute exacerbations was low and the difference in the rate of acute exacerbations did not reach statistical significance, it is interesting to note that there were no deaths associated with acute exacerbations in the lebrikizumab plus pirfenidone arm, while seven of 11 patients in the placebo plus pirfenidone arm died, consistent with reported rates of mortality post-acute exacerbation ≥50%.

also in 111,027 other papers